Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1866)	8/23/2007 6:52:40 PM
From: Steve Lokness	Read Replies (2) \| Respond to of 3722

Yup - very interesting. It started on anemic volume, but that did pick up a little during the day. IMCL vrs MIT should be very interesting if, IF, it goes to trial. Steve

To: Jibacoa who wrote (1866)	10/26/2007 4:57:07 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

RGEN Is trying to hold its near term support at the $4.25 level.<g> bigcharts.marketwatch.com It needs to close above $4.45 before it can test the resistance at the double top from the Sep6-Sep7 H at the $5.03 level bigcharts.marketwatch.com It should receive around $45M from the settlement with IMCL on the Erbitux claim, after deducting legal expenses & MIT's share of the $65M settlement & that will be > 2x the $21,816,000 it had in cash as of June 30.<g> The revenues for the 1stQ were 65% higher than the 2006 revenues $5,978,000 vs. $3,628,000 primarily due to better Protein A sales, & the gross profit was also 69% better than ib 2006. But the expenses were also 65% higher $5,993,000 vs. $3,750,000 mainly due to increased research, licensing & litigation expenses. The lawsuit that RGEN & the University of Michigan filed against BMY concerning the patent that covers a method of treating RA with CTLA4-Ig is pending & currently scheduled for trial in April 2008.(BMY's Orencia uses CTLA4-Ig & sales of Orencia are expected to reach $1B in the next 4 or 5 years.) This last lawsuit is the one that Peter was referring to in his comment in January 2005. Will see if RGEN can get similar gains from it as it did from the Erbitux claim.<g> Message 20984544 With some good news, it seems possible that RGEN may be able to test its Sep 2003 H at $8.47 for almost a 100% gain from present levels. The March 200 H at $18 seems too far away at present.<g> bigcharts.marketwatch.com Bernard